ect of RenaGel B , a non-absorbed , calcium-and aluminium-free phosphate binder , on serum phosphorus , calcium , and intact parathyroid hormone in end-stage renal disease patients
hormone (iPTH) levels from 292 pg/ml to 395 pg/ml. iPTH fell to 283 pg/ml after 6 weeks of RenaGel Background. Control of dietary phosphate absorption in end-stage renal disease patients is essential to prevent treatment despite a persistently lower serum calcium. RenaGel treatment also reduced serum total and LDL the deleterious sequelae of phosphorus retention. Efficacy of currently available calciumand aluminiumcholesterol by 25 mg/dl (0.65 mmol/l ) and 23 mg/dl (0.59 mmol/l ) respectively. containing phosphate binders is constrained by the side-effects associated with the absorption of calcium Conclusions. RenaGel appears to be an effective phosphate binder free of calcium and aluminium. and aluminium. The current study examined the efficacy of RenaGel, a calciumand aluminium-free, polyPhosphorus control with two to four RenaGel capsules per meal appears to result in comparable phosphorus meric phosphate binder, in end-stage renal disease patients. lowering seen with calciumor aluminium-based phosphate binders. RenaGel may offer an alternative for Methods. Administration of calciumor aluminiumcontaining phosphate binders ceased during a 2-week the control of phosphorus retention in end-stage renal disease patients. washout period. RenaGel, at starting doses of one, two, or three 500-mg capsules three times per day with meals, was administered for 8 weeks. RenaGel dose